Quick Takeaways
- CVRX - CVRx, Inc. has 26 insiders with reported activity on this page.
- Net insider value flow over the last year: +$381,877.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
- Holders
Insider Transactions Reported by 26 Insiders of CVRx, Inc.
- Symbol
- CVRX on Nasdaq
- Location
- Minneapolis, MN
What Changed
- Buy value: $1,369,494; sell value: $987,617.
- Net share flow: +151,906.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
Insider trading overview
Last 12 monthsNet insider flow leans to buying over the last 12 months. Net value: +$381,877.
Buys
$1,369,494
Shares: 252,829
Insiders: 3
Sells
$987,617
Shares: 100,923
Insiders: 6
Net
+$381,877
Shares: +151,906
Insiders: -3
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 47,400 | 16,017 | $300,377 | $126,575 | +$173,802 |
| 3-6 | 0 | 84,906 | $0 | $861,042 | -$861,042 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 205,429 | 0 | $1,069,117 | $0 | +$1,069,117 |
CVRx, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Johnson & Johnson Innovation - JJDC, Inc. | 10%+ Owner | $64,860,045 | Mixed | 15 Sep 2023 | ||
| JOHNSON & JOHNSON | 10%+ Owner | $40,369,355 | -$861,042 | -2.1% | Filing P/S | 26 Nov 2025 |
| NEW ENTERPRISE ASSOCIATES 10 L P | 10%+ Owner | $37,593,767 | Mixed | 02 Jul 2021 | ||
| Geoffrey B. Pardo | Director | $33,990,694 | Mixed | 02 Jul 2021 | ||
| GSK plc | 10%+ Owner | $18,695,602 | Mixed | 02 Jul 2021 | ||
| Kirk G. Nielsen | Director | $10,555,670 | +$1,037,142 | +11% | Mixed | 03 Jun 2025 |
| Mudit K. Jain | Director | $6,412,485 | +$308,152 | +5% | Mixed | 20 Feb 2026 |
| NEA PARTNERS 10 L P | 10%+ Owner | $3,217,197 | Mixed | 02 Jul 2021 | ||
| Kevin Hykes | PRES & CEO, Director | $3,007,107 | -$37,149 | -1.2% | Mixed | 27 Feb 2026 |
| Jared Oasheim | Chief Financial Officer | $933,819 | -$13,781 | -1.5% | Mixed | 27 Feb 2026 |
| Robert Allen John | Chief Revenue Officer | $875,257 | -$31,326 | -3.5% | Mixed | 27 Feb 2026 |
| Philip B. Adamson | Chief Medical Officer | $640,862 | -$9,973 | -1.5% | Mixed | 27 Feb 2026 |
| Paul Verrastro | Chief Mktg & Strat Officer | $601,864 | -$10,146 | -1.7% | Mixed | 27 Feb 2026 |
| Nadim Yared | CHIEF EXECUTIVE OFFICER, Director | $600,518 | Mixed | 02 Feb 2024 | ||
| John Brintnall | Chief Strategy Officer And Sec | $584,980 | Mixed | 22 Apr 2022 | ||
| Joseph P. Slattery | Director | $388,317 | Mixed | 03 Jun 2025 | ||
| Gregory Morrison | Chief Human Resources Officer | $206,720 | Mixed | 02 Mar 2026 | ||
| Brent Binkowski | Chief Operating Officer | $192,128 | Mixed | 27 Feb 2026 | ||
| Kevin J. Ballinger | Director | $185,775 | Mixed | 03 Jun 2025 | ||
| Mitch C. Hill | Director | $185,775 | Mixed | 03 Jun 2025 | ||
| Ali Behbahani | Director | $145,955 | Mixed | 04 Jun 2024 | ||
| Martha Shadan | Director | $140,092 | Mixed | 03 Jun 2025 | ||
| John M. Nehra | Director | $138,730 | Mixed | 07 Jun 2022 | ||
| Dean Bruhn-Ding | Vp Of Reg. Affairs And Qa | $30,846 | Mixed | 02 Aug 2022 | ||
| Liz Galle | Vp Of Global Clinical Research | $14,436 | Mixed | 16 Oct 2023 | ||
| Craig E. Palmer | Svp, U.S. Sales | $6,318 | Mixed | 25 Mar 2024 |
Top shareholders of CVRx, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Johnson & Johnson Innovation - JJDC, Inc. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,495,575
|
$64,860,045 | — | 15 Sep 2023 | |
| JOHNSON & JOHNSON |
3/4/5
13D/G
13F
|
10%+ Owner · Company |
15%
from 13D/G
|
4,024,861
|
$40,369,355 | -$861,042 | 26 Nov 2025 | |
| NEW ENTERPRISE ASSOCIATES 10 L P |
3/4/5
13D/G
|
10%+ Owner · New Enterprise Associates 10, Limited Partnership |
7.8%
from 13D/G
|
2,026,083
|
$37,593,767 | — | 02 Jul 2021 | |
| Geoffrey B. Pardo |
3/4/5
|
Director |
—
mixed-class rows
|
1,839,404
mixed-class rows
|
$33,990,694 | — | 02 Jul 2021 | |
| GSK plc |
3/4/5
13F
|
10%+ Owner · Company |
3.9%
from 13F
|
1,007,583
|
$18,695,602 | — | 02 Jul 2021 | |
| NEA Management Company, LLC |
13F
|
Company |
7.8%
|
2,026,083
|
$14,385,189 | — | 31 Dec 2025 | |
| Vensana Capital I GP, LLC |
13D/G
|
Kirk Nielsen |
7.2%
|
1,760,734
|
$11,849,740 | $0 | 31 Dec 2024 | |
| Kirk G. Nielsen |
3/4/5
|
Director |
—
mixed-class rows
|
1,929,688
mixed-class rows
|
$10,555,670 | +$1,037,142 | 03 Jun 2025 | |
| Gilde Healthcare IV U.a. Cooperatieve |
13D/G
|
Cooperatieve Gilde Healthcare IV U.A. |
4.9%
|
1,231,490
|
$8,287,928 | $0 | 04 Feb 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.3%
|
1,120,663
|
$7,956,707 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
|
Company |
4.1%
|
1,061,087
|
$7,533,717 | — | 31 Dec 2025 | |
| Mudit K. Jain |
3/4/5
|
Director |
—
mixed-class rows
|
1,005,387
mixed-class rows
|
$6,412,485 | +$308,152 | 20 Feb 2026 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
3.1%
|
814,943
|
$5,786,095 | — | 31 Dec 2025 | |
| SILVERCREST ASSET MANAGEMENT GROUP LLC |
13F
|
Company |
2.4%
|
634,639
|
$4,505,937 | — | 31 Dec 2025 | |
| NEA PARTNERS 10 L P |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
173,388
|
$3,217,197 | — | 02 Jul 2021 | |
| Kevin Hykes |
3/4/5
|
PRES & CEO, Director |
—
mixed-class rows
|
522,237
mixed-class rows
|
$3,007,107 | -$37,149 | 27 Feb 2026 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
1.6%
|
413,018
|
$2,932,428 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.5%
|
403,949
|
$2,869,069 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.5%
|
380,641
|
$2,702,551 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.2%
|
311,658
|
$2,212,772 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.2%
|
305,503
|
$2,169,071 | — | 31 Dec 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.86%
|
225,349
|
$1,599,978 | — | 31 Dec 2025 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.7%
|
183,531
|
$1,303,000 | — | 31 Dec 2025 | |
| FourWorld Capital Management LLC |
13F
|
Company |
0.69%
|
180,000
|
$1,278,000 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.68%
|
177,598
|
$1,260,946 | — | 31 Dec 2025 | |
| TUDOR INVESTMENT CORP ET AL |
13F
|
Company |
0.6%
|
157,260
|
$1,116,546 | — | 31 Dec 2025 | |
| MAIRS & POWER INC |
13F
|
Company |
0.55%
|
142,456
|
$1,011,438 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.53%
|
139,202
|
$988,334 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.53%
|
137,809
|
$978,445 | — | 31 Dec 2025 | |
| Jared Oasheim |
3/4/5
|
CHIEF FINANCIAL OFFICER |
—
mixed-class rows
|
187,703
mixed-class rows
|
$933,819 | -$13,781 | 27 Feb 2026 | |
| Robert Allen John |
3/4/5
|
Chief Revenue Officer |
—
mixed-class rows
|
138,036
mixed-class rows
|
$875,257 | -$31,326 | 27 Feb 2026 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.37%
|
96,212
|
$683,105 | — | 31 Dec 2025 | |
| Philip B. Adamson |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
123,578
mixed-class rows
|
$640,862 | -$9,973 | 27 Feb 2026 | |
| UBS Group AG |
13F
|
Company |
0.34%
|
88,401
|
$627,647 | — | 31 Dec 2025 | |
| Paul Verrastro |
3/4/5
|
CHIEF MKTG & STRAT OFFICER |
—
mixed-class rows
|
127,551
mixed-class rows
|
$601,864 | -$10,146 | 27 Feb 2026 | |
| Nadim Yared |
3/4/5
|
CHIEF EXECUTIVE OFFICER, Director |
—
mixed-class rows
|
48,305
mixed-class rows
|
$600,518 | — | 02 Feb 2024 | |
| John Brintnall |
3/4/5
|
CHIEF STRATEGY OFFICER AND SEC |
—
class O/S missing
|
31,527
|
$584,980 | — | 22 Apr 2022 | |
| Quantinno Capital Management LP |
13F
|
Company |
0.29%
|
75,973
|
$539,408 | — | 31 Dec 2025 | |
| Cresset Asset Management, LLC |
13F
|
Company |
0.27%
|
71,802
|
$509,794 | — | 31 Dec 2025 | |
| AlphaQuest LLC |
13F
|
Company |
0.27%
|
70,795
|
$502,645 | — | 31 Dec 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.24%
|
62,599
|
$444,453 | — | 31 Dec 2025 | |
| Joseph P. Slattery |
3/4/5
|
Director |
—
mixed-class rows
|
50,199
mixed-class rows
|
$388,317 | — | 03 Jun 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.21%
|
54,000
|
$383,400 | — | 31 Dec 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.2%
|
53,183
|
$377,691 | — | 31 Dec 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.19%
|
49,991
|
$354,935 | — | 31 Dec 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.19%
|
49,827
|
$353,773 | — | 31 Dec 2025 | |
| WEXFORD CAPITAL LP |
13F
|
Company |
0.18%
|
48,105
|
$341,550 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.18%
|
45,941
|
$326,181 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.17%
|
44,494
|
$315,907 | — | 31 Dec 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.16%
|
42,289
|
$300,252 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for CVRx, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Philip B. Adamson | CVRX | Common Stock | Sale | -2.01% | $9,973 | $7.90 | -1,262 | 61,578 | 02 Mar 2026 | Direct |
| Gregory Morrison | CVRX | Common Stock | Award | 34,000 | 34,000 | 02 Mar 2026 | Direct | |||
| Gregory Morrison | CVRX | Stock Option (right to buy) | Award | 154,500 | 154,500 | 02 Mar 2026 | Direct | |||
| Kevin Hykes | CVRX | Common Stock | Sale | -2.66% | $61,349 | $7.90 | -7,763 | 284,237 | 02 Mar 2026 | Direct |
| Paul Verrastro | CVRX | Common Stock | Sale | -2.08% | $10,146 | $7.90 | -1,284 | 60,551 | 02 Mar 2026 | Direct |
| Jared Oasheim | CVRX | Common Stock | Sale | -1.77% | $13,781 | $7.90 | -1,744 | 96,703 | 02 Mar 2026 | Direct |
| Robert Allen John | CVRX | Common Stock | Sale | -4.4% | $31,326 | $7.90 | -3,964 | 86,036 | 02 Mar 2026 | Direct |
| Philip B. Adamson | CVRX | Common Stock | Award | 187.7% | 41,000 | 62,840 | 27 Feb 2026 | Direct | ||
| Philip B. Adamson | CVRX | Stock Option (right to buy) | Award | 62,000 | 62,000 | 27 Feb 2026 | Direct | |||
| Kevin Hykes | CVRX | Common Stock | Award | 119.6% | 159,000 | 292,000 | 27 Feb 2026 | Direct | ||
| Kevin Hykes | CVRX | Stock Option (right to buy) | Award | 238,000 | 238,000 | 27 Feb 2026 | Direct | |||
| Paul Verrastro | CVRX | Common Stock | Award | 267.3% | 45,000 | 61,835 | 27 Feb 2026 | Direct | ||
| Paul Verrastro | CVRX | Stock Option (right to buy) | Award | 67,000 | 67,000 | 27 Feb 2026 | Direct | |||
| Jared Oasheim | CVRX | Common Stock | Award | 162.9% | 61,000 | 98,447 | 27 Feb 2026 | Direct | ||
| Jared Oasheim | CVRX | Stock Option (right to buy) | Award | 91,000 | 91,000 | 27 Feb 2026 | Direct | |||
| Robert Allen John | CVRX | Common Stock | Award | 63.6% | 35,000 | 90,000 | 27 Feb 2026 | Direct | ||
| Robert Allen John | CVRX | Stock Option (right to buy) | Award | 52,000 | 52,000 | 27 Feb 2026 | Direct | |||
| Brent Binkowski | CVRX | Common Stock | Award | 90.4% | 15,000 | 31,600 | 27 Feb 2026 | Direct | ||
| Brent Binkowski | CVRX | Stock Option (right to buy) | Award | 23,000 | 23,000 | 27 Feb 2026 | Direct | |||
| Mudit K. Jain | CVRX | Common Stock | Purchase | 5.01% | $297,592 | $6.36 | 46,800 | 980,183 | 20 Feb 2026 | See footnote |
| Mudit K. Jain | CVRX | Common Stock | Purchase | 11.9% | $2,785 | $4.64 | 600 | 5,650 | 18 Feb 2026 | Direct |
| Johnson & Johnson | CVRX | Common Stock | Sale | -0.16% | $63,560 | $10.03 | -6,337 | 4,024,861 | 26 Nov 2025 | By Johnson & Johnson Innovation - JJDC, Inc. |
| Johnson & Johnson | CVRX | Common Stock | Sale | -0.16% | $63,560 | $10.03 | -6,337 | 4,040,861 | 26 Nov 2025 | By Johnson & Johnson Innovation - JJDC, Inc. |
| Johnson & Johnson | CVRX | Common Stock | Sale | -0.4% | $160,480 | $10.03 | -16,000 | 4,031,198 | 25 Nov 2025 | By Johnson & Johnson Innovation - JJDC, Inc. |
| Johnson & Johnson | CVRX | Common Stock | Sale | -0.05% | $22,132 | $10.06 | -2,200 | 4,047,198 | 24 Nov 2025 | By Johnson & Johnson Innovation - JJDC, Inc. |
| Johnson & Johnson | CVRX | Common Stock | Sale | -0.01% | $5,000 | $10.00 | -500 | 4,049,398 | 21 Nov 2025 | By Johnson & Johnson Innovation - JJDC, Inc. |
| Johnson & Johnson | CVRX | Common Stock | Sale | -0.02% | $10,000 | $10.00 | -1,000 | 4,049,898 | 12 Nov 2025 | By Johnson & Johnson Innovation - JJDC, Inc. |
| Johnson & Johnson | CVRX | Common Stock | Sale | $2,000 | $10.00 | -200 | 4,050,898 | 07 Nov 2025 | By Johnson & Johnson Innovation - JJDC, Inc. | |
| Johnson & Johnson | CVRX | Common Stock | Sale | -1.28% | $534,310 | $10.21 | -52,332 | 4,051,098 | 06 Nov 2025 | By Johnson & Johnson Innovation - JJDC, Inc. |
| Brent Binkowski | CVRX | Common Stock | Award | 16,600 | 16,600 | 11 Aug 2025 | Direct | |||
| Brent Binkowski | CVRX | Stock Option (right to buy) | Award | 74,900 | 74,900 | 11 Aug 2025 | Direct | |||
| Kirk G. Nielsen | CVRX | Stock Option (right to buy) | Award | 19,554 | 19,554 | 03 Jun 2025 | Direct | |||
| Mudit K. Jain | CVRX | Stock Option (right to buy) | Award | 19,554 | 19,554 | 03 Jun 2025 | Direct | |||
| Joseph P. Slattery | CVRX | Stock Option (right to buy) | Award | 19,554 | 19,554 | 03 Jun 2025 | Direct | |||
| Mitch C. Hill | CVRX | Stock Option (right to buy) | Award | 19,554 | 19,554 | 03 Jun 2025 | Direct | |||
| Kevin J. Ballinger | CVRX | Stock Option (right to buy) | Award | 19,554 | 19,554 | 03 Jun 2025 | Direct | |||
| Martha Shadan | CVRX | Stock Option (right to buy) | Award | 19,554 | 19,554 | 03 Jun 2025 | Direct | |||
| Kirk G. Nielsen | CVRX | Common Stock | Purchase | 0.58% | $59,795 | $5.45 | 10,966 | 1,910,134 | 15 May 2025 | See Footnote |
| Kirk G. Nielsen | CVRX | Common Stock | Purchase | 3.33% | $320,364 | $5.23 | 61,200 | 1,899,168 | 14 May 2025 | See Footnote |
| Kirk G. Nielsen | CVRX | Common Stock | Purchase | 5.84% | $536,313 | $5.29 | 101,413 | 1,837,968 | 13 May 2025 | See Footnote |
| Mudit K. Jain | CVRX | Common Stock | Purchase | 3.06% | $789 | $5.26 | 150 | 5,050 | 13 May 2025 | Direct |
| Kirk G. Nielsen | CVRX | Common Stock | Purchase | 1.47% | $120,670 | $4.79 | 25,200 | 1,736,555 | 12 May 2025 | See Footnote |
| Mudit K. Jain | CVRX | Common Stock | Purchase | 44.1% | $6,986 | $4.66 | 1,500 | 4,900 | 12 May 2025 | Direct |
| Kevin Hykes | CVRX | Common Stock | Purchase | 3.91% | $24,200 | $4.84 | 5,000 | 133,000 | 12 May 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.